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ABSTRACT
Objective: We tested the hypothesis that olfactory function is more impaired in patients with pri-
mary progressive MS (PPMS) than that in relapsing-remitting MS (RRMS).
Methods: Standardized olfactory testing was performed in 32 patients with PPMS, 32 patients
with RRMS, and 32 healthy controls (HCs). Patients with olfactory dysfunction due to an alterna-
tive primary etiology were excluded. The validated olfactory testing method yielded individual
scores for olfactory threshold, odor discrimination, and odor identification, alongwith a composite
Threshold Discrimination Identification (TDI) score.
Results: Olfactory dysfunction was identified in 27 (84%) patients with PPMS, 10 (31%) pa-
tients with RRMS, and 1 (3%) HC. While age and sex were similar between PPMS and HCs,
the TDI score and all olfactory subscores were significantly worse in patients with PPMS com-
pared with HCs (all p, 0.001). After adjustment for differences in age, sex, Expanded Disability
Status Scale (EDSS), and disease duration, odor discrimination, odor identification, and the
composite TDI score were worse in patients with PPMS vs RRMS (p 5 0.03, 0.04, and 0.02,
respectively). Neither age, sex, EDSS, nor disease duration was significantly associated with the
composite TDI score.
Conclusions: Olfactory dysfunction was more frequent and severe in PPMS compared with RRMS,
independent of disease duration and overall disability status. Further research on cellular level differ-
ences in olfactory neural pathways may lead to new insights about disease pathogenesis in MS.
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GLOSSARY
EDSS 5 Expanded Disability Status Scale; HC 5 healthy control; PPMS 5 primary progressive MS; RRMS 5 relapsing-
remitting MS; TDI 5 Threshold Discrimination Identification.
MS is a chronic inflammatory demyelinating disease of the CNS, which typically follows a relaps-
ing-remitting disease course (relapsing-remitting MS [RRMS]). However, approximately 15%
of all patients with MS initially present with a primary progressive disease course (primary pro-
gressive MS [PPMS]) characterized by steadily increasing neurologic disability without recov-
ery.1 Some evidence suggests that—albeit part of the same underlying pathobiology—PPMS
presents a less inflammatory course of MS.2
Different studies have reported olfactory dysfunction in patients with MS at rates of 20%–
40% in cohorts comprised mostly of RRMS.3 The underlying pathophysiologic distinctives
leading to PPMS vs RRMS are not well understood. Differences in the pattern of disease
symptomatology may identify opportunities to better understand disease pathophysiology.
Exploring for differences in olfactory dysfunction between PPMS and RRMS has been
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identified by other experts as a gap in the lit-
erature and potential area for future research.3
As such, we sought to test the hypothesis that
olfactory sense impairment is present in pa-
tients with PPMS, and that olfactory dysfunc-
tion is more severe in PPMS than in RRMS.
METHODS Subjects. Standardized olfactory function testing
was performed in patients diagnosed with PPMS and RRMS ac-
cording to the 2010 McDonald criteria4 and in age-matched
healthy controls (HCs). Predefined exclusion criteria were as
follows: age younger than 18 or older than 70 years, pregnancy,
olfactory disorders with a known different etiology (post-
traumatic, postinfectious, sinonasal, infections of the upper
respiratory tract, allergies, tumors treated with chemotherapy or
radiation, depression, and Parkinson or Alzheimer disease), and
patients taking medications that could cause olfactory dysfunc-
tion (e.g., amitriptyline, methotrexate, and doxycycline),
including patients who had received corticosteroid treatment
within the last 3 months since corticosteroids can also affect the
olfactory function.5 We used the Expanded Disability Status
Scale (EDSS) to measure physical disability.
Olfactory testing. The Threshold Discrimination Identifica-
tion (TDI) Test was used for orthonasal olfactory testing.6 The
olfactory threshold (T) was measured using 48 Sniffin’ Sticks with
a 16-stage dilution series of n-butanol. The discrimination test
(D) was performed with 48 Sniffin’ Sticks of different smell
qualities to test the distinction of smells. Everyday odors were
identified with the identification test, which consisted of 16 Snif-
fin’ Sticks. A TDI value of less than 16 points was defined as
anosmia, up to 31 points as hyposmia, and a value above 31
points as normosmia.6
Data analysis. Olfactory function measures in patients with
PPMS were compared with HCs and patients with RRMS using
the Fisher exact test for categorical variables and the Student t test
for continuous variables after confirming normality. There were
no differences in age or sex between the PPMS and HC cohorts,
although differences were identified between the PPMS and
RRMS cohorts. To isolate the effect of PPMS vs RRMS pathol-
ogy, we created linear regression models for each olfactory mea-
sure that included terms for MS subtype (PPMS vs RRMS), age,
sex, EDSS, and disease duration. Statistical analyses were per-
formed using SPSS 23.0 (IBM SPSS Statistics, Armonk, NY).
The study was approved by the medical ethics committee of
Charité–Universitätsmedizin Berlin and was conducted in
accordance with the Declaration of Helsinki and its currently
applicable version and applicable German laws. All participants
provided written informed consent to participate in the study.
RESULTS We studied 96 subjects, 32 with PPMS,
32 with RRMS, and 32 HCs. The demographics
and clinical characteristics of study participants are
shown in table 1. In the PPMS cohort, 26 (81%)
were hyposmic and 4 (13%) anosmic, whereas 13
(41%) patients with RRMS were hyposmic and
none were anosmic. Olfactory test results of the 3
cohorts and univariate differences in those character-
istics are summarized in table 1 and presented in the
figure. Of 16 possible points, the observed range of
olfactory function scores was 0–12 for odor thresh-
old, 5–16 for odor discrimination, and 1–16 for
odor identification.
There were no significant differences in age or sex
between the PPMS and HC groups. Patients with
PPMS were found to have diminished odor thresh-
old, odor discrimination, and odor identification, re-
sulting in a lower composite olfactory function score
compared with HCs. Univariate analysis also showed
Table 1 Patient characteristics
Diagnosis PPMS RRMS Controls
p Value (PPMS
vs RRMS)
p Value (PPMS
vs controls)
p Value (RRMS
vs controls)
No. of cases 32 32 32
Age, y 53.4 6 9.3 35.5 6 9.3 51.9 6 17.6 ,0.001 0.68 ,0.001
Sex (female) 13 (40.6) 22 (68.8) 17 (53.1) 0.044 0.45 0.31
Odor threshold 5.3 6 2.6 6.8 6 2.2 7.8 6 1.4 0.016 ,0.001 0.034
Odor discrimination 9.3 6 2.2 12.4 6 2.3 12.3 6 1.4 ,0.001 ,0.001 0.84
Odor identification 10.9 6 3.7 13.0 6 1.5 14.6 6 0.7 0.004 ,0.001 ,0.001
Composite (TDI) 25.4 6 6.1 32.2 6 4.2 34.8 6 2.1 ,0.001 ,0.001
Qualitative olfactory
status
Normal 2 (6) 19 (59) 31 (97) ,0.001 ,0.001 ,0.001
Hyposmic 26 (81) 13 (41) 1 (3)
Anosmic 4 (13) 0 (0) 0 (0)
EDSS 4.9 6 2.1 2.6 6 1.8 NA ,0.001 NA NA
Disease duration, y 11.3 6 8.4 5.6 6 5.9 NA 0.002 NA NA
Abbreviations: EDSS 5 Expanded Disability Status Scale; NA 5 not applicable; PPMS 5 primary progressive MS; RRMS 5
relapsing-remitting MS; TDI 5 Threshold Discrimination Identification.
All values are presented in mean 6 SD or n (%) unless otherwise specified.
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that patients with PPMS had lower odor threshold,
discrimination, identification, and composite TDI
score compared with patients with RRMS, although
patients with PPMS also had worse EDSS and longer
disease duration as well as differences in age and sex.
Multivariate models that adjusted for age, sex,
EDSS, and disease duration found that PPMS diag-
nosis was still associated with worse odor discrimina-
tion, identification, and composite TDI score
compared with RRMS after adjustment for covari-
ates, although no difference in odor threshold. There
were no associations between any other patient char-
acteristics and olfactory function measures except
that higher EDSS was associated with diminished
odor discrimination (table 2).
DISCUSSION This study shows that patients with
PPMS have significantly decreased olfactory function
compared with HCs. Moreover, in comparison with
a cohort of patients with RRMS, PPMS diagnosis
was an independent predictor of worse olfactory
function after adjustment for important covariates,
whereas a standardized measure of disease disability
(EDSS) and disease duration did not emerge as signif-
icant contributor to olfactory function.
Previous studies investigating olfactory function in
patients with MS primarily included patients with
RRMS. A decreased odor threshold was found in pa-
tients with clinically isolated syndrome and early dis-
ease stages of RRMS, whereas odor discrimination
and odor identification were more often affected in
later disease stages.3 A single study has reported olfac-
tory assessments in patients with PPMS by testing
odor identification alone and found mild impairment
(13% affected).7 We have now demonstrated a signif-
icantly worse olfactory function in PPMS as com-
pared to RRMS and further provide a model that
adjusts for the significant baseline differences in dis-
ease duration and EDSS to show that the differences
are not merely reflective of general disease burden but
seem to be particular to disease subtype.7 It is impor-
tant that we also found a much higher rate of olfac-
tory impairment than in the prior cited study,
suggesting that our testing method may be more
sensitive.
The reasons for olfactory dysfunction in patients
with MS are not well understood.3 A human autopsy
cohort reported demyelination in parts of the olfac-
tory pathway in 71% of pathologically confirmed MS
cases.8 Decreased olfactory bulb volume is correlated
with increased MS lesion load in the olfactory brain,
both of which are linked to impaired olfactory func-
tion.3,9 Olfactory dysfunction is sometimes recog-
nized in the context of acute relapses as well,
implicating inflammatory damage.10 Observed differ-
ences between PPMS and RRMS, independent of
other disease severity measures, suggest that PPMS
may uniquely affect the olfactory brain tissue more
than RRMS.
Although the olfactory testing techniques used
here were robust, we did not use MRI to measure
the lesion load and atrophy of the olfactory pathway
Table 2 Linear regression models for olfactory function measures
Olfactory
measure Threshold Discrimination Identification Composite (TDI)
PPMS diagnosis
(vs RRMS)
20.86 (22.71 to 0.99), p 5 0.36 21.87 (23.54 to 20.20), p 5 0.03a 22.32 (24.55 to 20.10), p 5 0.04a 25.00 (29.05 to 20.95), p 5 0.02a
Age, y 20.04 (20.11 to 0.04), p 5 0.31 20.04 (20.10 to 0.03), p 5 0.28 0.02 (20.07 to 0.11), p 5 0.61 20.06 (20.22 to 0.11), p 5 0.49
Female sex 20.41 (21.76 to 0.94), p 5 0.54 0.25 (20.97 to 1.47), p 5 0.68 20.06 (21.68 to 1.56), p 5 0.94 20.19 (23.14 to 2.77), p 5 0.90
EDSS 20.19 (20.54 to 0.16), p 5 0.28 20.35 (20.67 to 20.03), p 5 0.03a 20.1 (20.52 to 0.33), p 5 0.66 20.64 (21.42 to 0.14), p 5 0.10
Disease
duration, y
0.07 (20.03 to 0.17), p 5 0.16 0.04 (20.04 to 0.13), p 5 0.32 0.00 (20.12 to 0.11), p 5 0.94 0.11 (20.10 to 0.33), p 5 0.30
Abbreviations: EDSS 5 Expanded Disability Status Scale; PPMS 5 primary progressive MS; RRMS 5 relapsing-remitting MS; TDI 5 Threshold Discrim-
ination Identification.
a Significant.
Figure Olfactory function test results: differences of Threshold Discrimination
Identification composite score and all individual olfactory subscores
between 3 cohorts
Results are displayed with mean and SDs. Controls 5 healthy controls; PPMS 5 primary
progressive MS; RRMS 5 relapsing-remitting MS; TDI 5 Threshold Discrimination
Identification.
Neurology: Neuroimmunology & Neuroinflammation 3
and compare it with other regions of the brain, which
may have helped clarify the etiology of the differences
we observed between the PPMS and RRMS groups.
At this time, techniques to accurately measure lesion
burden in the small structures comprising the olfac-
tory system are not well established or anatomically-
pathologically validated. Finally, although we con-
structed a multivariate model to control for important
disease covariates such as age and overall disability,
the size of our cohort is relatively small, and we can-
not exclude the possibility that the relationship
between the MS subgroup and olfactory dysfunction
is mediated or confounded by a variable we did not
measure, or incompletely adjusted for age, sex, EDSS,
and disease duration.
We conclude that olfactory dysfunction is a frequent
symptom in patients with PPMS, leading to severe
olfactory impairment, and is uniquely more severe in
PPMS compared with RRMS. The findings suggest
that olfactory dysfunction might be a surrogate of neu-
rodegeneration in these patients. Studies correlating
olfactory function with radiologic and clinical markers
of disease progression would be of interest.
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